LegalJul 15, 2026, 06:36 AM
CASI Pharma Wins Arbitration, Awarded Over RMB 100M
AI Summary
CASI Pharmaceuticals announced it received a final award from the Hong Kong International Arbitration Centre (HKIAC) in its arbitration proceeding against Juventas Co., Ltd. The tribunal rejected all of Juventas's claims of breach by CASI and determined Juventas had wrongfully terminated their agreements. As a result, CASI Pharmaceuticals was awarded over RMB 100 million, covering wasted costs, interest, arbitral costs, and a substantial portion of legal fees.
Key Highlights
- Arbitral tribunal rejected all of Juventas's allegations that CASI Pharmaceuticals breached agreements.
- Tribunal determined Juventas wrongfully terminated agreements related to CNCT-19 commercialization.
- CASI Pharmaceuticals was awarded all wasted costs and interest from the date of wrongful termination.
- The award includes CASI's share of arbitral tribunal and HKIAC costs.
- A substantial portion of CASI's legal costs incurred in pursuing arbitration was also awarded.
- Total award to CASI Pharmaceuticals is well over RMB 100 million.
Price Impact
More from CASIF